{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-003933","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.726988+00:00","generated_at":"2026-06-09T23:29:14.748906+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MoonLake announces positive 24-week Phase 2 MIRA results; 57% HiSCR75, 120mg dose confirmed for Phase 3","bullets":["57% of patients on sonelokimab 120mg achieved HiSCR75 at week 24 (+10 ppt from week 12); 38% achieved HiSCR90 (+14 ppt).","Complete inflammatory remission (IHS4-100) in 24% of patients; 31% AN 100 and 49% DT 100 at week 24 with 120mg.","120mg Q4W maintenance dose confirmed as optimal based on efficacy, safety, and pharmacokinetics; safety consistent with IL-17 class.","Adalimumab non-responders switching to sonelokimab at week 12 achieved HiSCR75 rates similar to patients randomized to sonelokimab at baseline.","Company on track to discuss Phase 3 development plans with FDA by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-003933","json":"https://secwatch.observer/filing/0001013762-23-003933.json","markdown":"https://secwatch.observer/filing/0001013762-23-003933.md","text":"https://secwatch.observer/filing/0001013762-23-003933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000101376223003933/0001013762-23-003933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000101376223003933/ea186779-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:29:14.748906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}